Precision Psychiatry Market Report by Product Type (Products, Services), Sample (Blood-Based, Non-Blood-Based), Biomarker Type (Genetic Biomarker, Protein Biomarker), Technology (Sequencing, Polymerase Chain Reaction (PCR), Microarray, Immunoassay, Liquid

Precision Psychiatry Market Report by Product Type (Products, Services), Sample (Blood-Based, Non-Blood-Based), Biomarker Type (Genetic Biomarker, Protein Biomarker), Technology (Sequencing, Polymerase Chain Reaction (PCR), Microarray, Immunoassay, Liquid Chromatography-Mass Spectrometry (LC-MS), and Others), Application (Alzheimer’s Disease, Parkinson’s Disease, Autism, Depression, Bipolar Disease, and Others), End User (Hospitals and Diagnostic Laboratories, Academic and Research Institutions, and Others), and Region 2024-2032


The global precision psychiatry market size reached US$ 1,059.7 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 4,027.9 Million by 2032, exhibiting a growth rate (CAGR) of 15.5% during 2024-2032. The rising prevalence of mental health disorders among the masses, the growing need for personalized treatment plans and interventions and the advent of genetic testing, and data analytics represent some of the key factors driving the market.

Precision psychiatry refers to an innovative medical approach that is widely adopted for mental health care. It leverages numerous advanced technologies and personalized medicine to provide more targeted and effective treatments for individuals suffering from psychiatric disorders. It recognizes that mental illnesses, such as depression, anxiety, bipolar disorder, and schizophrenia, are complex and multifaceted conditions influenced by a combination of genetic, environmental, and lifestyle factors. It aims to tailor multiple interventions based on an individual's unique characteristics, including their genetic makeup, neurobiological markers, and personal circumstances. It allows clinicians to gain deeper insights into the underlying mechanisms of psychiatric disorders and develop personalized treatment plans accordingly. Besides this, it also identifies specific genetic variations that may contribute to the susceptibility to certain mental health conditions or influence the response to particular medications. This information allows for the selection of more appropriate and targeted treatment options, increasing the likelihood of positive outcomes while minimizing the potential for adverse effects.

Precision Psychiatry Market Trends:
The global market is majorly driven by the rising prevalence of mental health disorders among the masses. Coupled with the growing need for personalized treatment plans and interventions, there has been a considerable increase in the adoption of precision psychiatry among individuals. Since precision psychiatry aligns with the broader trend toward personalized medicine across various medical fields. It recognizes that each individual is unique and requires tailored treatments based on their genetic, neurobiological, and environmental factors. This personalized approach resonates with patients, as it offers the prospect of more effective treatments and improved outcomes, which is gaining widespread prominence among the masses. Moreover, continual technological advancements, such as the advent of genetic testing, neuroimaging, and data analytics have significantly contributed to the development and implementation of precision psychiatry, further impacting the market favorably. Apart from this, the growing interest in precision psychiatry is accompanied by rising research activities and funding support. Academic institutions, research organizations, and pharmaceutical companies are investing in research to better understand the biological mechanisms of psychiatric disorders and develop targeted treatments, hence providing an impetus to the market. Other factors, including rapid urbanization, growing awareness among individuals and continual developments in the healthcare infrastructure, are also positively influencing the market.

Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each segment of the global precision psychiatry market report, along with forecasts at the global, regional, and country levels from 2024-2032. Our report has categorized the market based on product type, sample, biomarker type, technology, application, and end user.

Product Type Insights:

Products
Services

The report has provided a detailed breakup and analysis of the precision psychiatry market based on the product type. This includes products and services. According to the report, products represented the largest segment.

Sample Insights:

Blood-Based
Non-Blood-Based
Saliva
Urine
Cerebral Spinal Fluid (CSF)
Others

A detailed breakup and analysis of the precision psychiatry market based on the sample has also been provided in the report. This includes blood-based and non-blood-based (saliva, urine, cerebral spinal fluid (CSF), and others). According to the report, non-blood-based accounted for the largest market share.

Biomarker Type Insights:

Genetic Biomarker
Protein Biomarker

The report has provided a detailed breakup and analysis of the precision psychiatry market based on the biomarker type. This includes genetic biomarker and protein biomarker. According to the report, protein biomarker exhibits a clear dominance in the market.

Technology Insights:

Sequencing
Next-Generation Sequencing (NGS)
Sanger Sequencing
Polymerase Chain Reaction (PCR)
Real-Time Polymerase Chain Reaction (RT-PCR)
Digital Polymerase Chain Reaction (dPCR)
Microarray
Immunoassay
Liquid Chromatography-Mass Spectrometry (LC-MS)
Others

The report has provided a detailed breakup and analysis of the precision psychiatry market based on the technology. This includes sequencing [next-generation sequencing (NGS) and sanger sequencing], polymerase chain reaction (PCR) [real-time polymerase chain reaction (RT-PCR) and digital polymerase chain reaction (dPCR)], microarray, immunoassay, liquid chromatography-mass spectrometry (LC-MS), and others. According to the report, sequencing represented the largest segment.

Application Insights:

Alzheimer’s Disease
Parkinson’s Disease
Autism
Depression
Bipolar Disease
Others

A detailed breakup and analysis of the precision psychiatry market based on the application has also been provided in the report. This includes Alzheimer’s disease, Parkinson’s disease, autism, depression, bipolar disease, and others. According to the report, depression accounted for the largest market share.

End User Insights:

Hospitals and Diagnostic Laboratories
Academic and Research Institutions
Others

The report has provided a detailed breakup and analysis of the precision psychiatry market based on the end user. This includes hospitals and diagnostic laboratories, academic and research institutions and others. According to the report, hospitals and diagnostic laboratories exhibits a clear dominance in the market.

Regional Insights:

North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for precision psychiatry. Some of the factors driving the North America precision psychiatry market included the growing awareness among the masses, the emerging healthcare industry, the shifting lifestyle preferences of the masses, etc.

Competitive Landscape:
The report has also provided a comprehensive analysis of the competitive landscape in the global precision psychiatry market. Detailed profiles of all major companies have been provided. Some of the companies covered include Altimate Healthcare, Alto Nanoscience, ATAI Life Sciences N.V., Fulgent Genetics Inc, Invitae Corporation, Myriad Genetics Inc., Precision Psychiatric Services Inc., Tempus Labs Inc., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in This Report:
How has the global precision psychiatry market performed so far, and how will it perform in the coming years?
What are the drivers, restraints, and opportunities in the global precision psychiatry market?
What is the impact of each driver, restraint, and opportunity on the global precision psychiatry market?
What are the key regional markets?
Which countries represent the most attractive precision psychiatry market?
What is the breakup of the market based on the product type?
Which is the most attractive product type in the precision psychiatry market?
What is the breakup of the market based on the sample?
Which is the most attractive sample in the precision psychiatry market?
What is the breakup of the market based on the biomarker type?
Which is the most attractive biomarker type in the precision psychiatry market?
What is the breakup of the market based on technology?
Which is the most attractive technology in the precision psychiatry market?
What is the breakup of the market based on the application?
Which is the most attractive application in the precision psychiatry market?
What is the breakup of the market based on the end user?
Which is the most attractive end user in the precision psychiatry market?
What is the competitive structure of the global precision psychiatry market?
Who are the key players/companies in the global precision psychiatry market?


1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Precision Psychiatry Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Product Type
6.1 Products
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Services
6.2.1 Market Trends
6.2.2 Market Forecast
7 Market Breakup by Sample
7.1 Blood-Based
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Non-Blood-Based
7.2.1 Market Trends
7.2.2 Key Segments
7.2.2.1 Saliva
7.2.2.2 Urine
7.2.2.3 Cerebral Spinal Fluid (CSF)
7.2.2.4 Others
7.2.3 Market Forecast
8 Market Breakup by Biomarker Type
8.1 Genetic Biomarker
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Protein Biomarker
8.2.1 Market Trends
8.2.2 Market Forecast
9 Market Breakup by Technology
9.1 Sequencing
9.1.1 Market Trends
9.2.2 Key Segments
9.2.2.1 Next-Generation Sequencing (NGS)
9.2.2.2 Sanger Sequencing
9.1.3 Market Forecast
9.2 Polymerase Chain Reaction (PCR)
9.2.1 Market Trends
9.2.2 Key Segments
9.2.2.1 Real-Time Polymerase Chain Reaction (RT-PCR)
9.2.2.2 Digital Polymerase Chain Reaction (dPCR)
9.2.3 Market Forecast
9.3 Microarray
9.3.1 Market Trends
9.3.2 Market Forecast
9.4 Immunoassay
9.4.1 Market Trends
9.4.2 Market Forecast
9.5 Liquid Chromatography-Mass Spectrometry (LC-MS)
9.5.1 Market Trends
9.5.2 Market Forecast
9.6 Others
9.6.1 Market Trends
9.6.2 Market Forecast
10 Market Breakup by Application
10.1 Alzheimer’s Disease
10.1.1 Market Trends
10.1.2 Market Forecast
10.2 Parkinson’s Disease
10.2.1 Market Trends
10.2.2 Market Forecast
10.3 Autism
10.3.1 Market Trends
10.3.2 Market Forecast
10.4 Depression
10.4.1 Market Trends
10.4.2 Market Forecast
10.5 Bipolar Disease
10.5.1 Market Trends
10.5.2 Market Forecast
10.6 Others
10.6.1 Market Trends
10.6.2 Market Forecast
11 Market Breakup by End User
11.1 Hospitals and Diagnostic Laboratories
11.1.1 Market Trends
11.1.2 Market Forecast
11.2 Academic and Research Institutions
11.2.1 Market Trends
11.2.2 Market Forecast
11.3 Others
11.3.1 Market Trends
11.3.2 Market Forecast
12 Market Breakup by Region
12.1 North America
12.1.1 United States
12.1.1.1 Market Trends
12.1.1.2 Market Forecast
12.1.2 Canada
12.1.2.1 Market Trends
12.1.2.2 Market Forecast
12.2 Asia-Pacific
12.2.1 China
12.2.1.1 Market Trends
12.2.1.2 Market Forecast
12.2.2 Japan
12.2.2.1 Market Trends
12.2.2.2 Market Forecast
12.2.3 India
12.2.3.1 Market Trends
12.2.3.2 Market Forecast
12.2.4 South Korea
12.2.4.1 Market Trends
12.2.4.2 Market Forecast
12.2.5 Australia
12.2.5.1 Market Trends
12.2.5.2 Market Forecast
12.2.6 Indonesia
12.2.6.1 Market Trends
12.2.6.2 Market Forecast
12.2.7 Others
12.2.7.1 Market Trends
12.2.7.2 Market Forecast
12.3 Europe
12.3.1 Germany
12.3.1.1 Market Trends
12.3.1.2 Market Forecast
12.3.2 France
12.3.2.1 Market Trends
12.3.2.2 Market Forecast
12.3.3 United Kingdom
12.3.3.1 Market Trends
12.3.3.2 Market Forecast
12.3.4 Italy
12.3.4.1 Market Trends
12.3.4.2 Market Forecast
12.3.5 Spain
12.3.5.1 Market Trends
12.3.5.2 Market Forecast
12.3.6 Russia
12.3.6.1 Market Trends
12.3.6.2 Market Forecast
12.3.7 Others
12.3.7.1 Market Trends
12.3.7.2 Market Forecast
12.4 Latin America
12.4.1 Brazil
12.4.1.1 Market Trends
12.4.1.2 Market Forecast
12.4.2 Mexico
12.4.2.1 Market Trends
12.4.2.2 Market Forecast
12.4.3 Others
12.4.3.1 Market Trends
12.4.3.2 Market Forecast
12.5 Middle East and Africa
12.5.1 Market Trends
12.5.2 Market Breakup by Country
12.5.3 Market Forecast
13 Drivers, Restraints, and Opportunities
13.1 Overview
13.2 Drivers
13.3 Restraints
13.4 Opportunities
14 Value Chain Analysis
15 Porters Five Forces Analysis
15.1 Overview
15.2 Bargaining Power of Buyers
15.3 Bargaining Power of Suppliers
15.4 Degree of Competition
15.5 Threat of New Entrants
15.6 Threat of Substitutes
16 Price Analysis
17 Competitive Landscape
17.1 Market Structure
17.2 Key Players
17.3 Profiles of Key Players
17.3.1 Altimate Healthcare
17.3.1.1 Company Overview
17.3.1.2 Product Portfolio
17.3.2 Alto Nanoscience
17.3.2.1 Company Overview
17.3.2.2 Product Portfolio
17.3.3 ATAI Life Sciences N.V.
17.3.3.1 Company Overview
17.3.3.2 Product Portfolio
17.3.4 Fulgent Genetics Inc.
17.3.4.1 Company Overview
17.3.4.2 Product Portfolio
17.3.5 Invitae Corporation
17.3.5.1 Company Overview
17.3.5.2 Product Portfolio
17.3.6 Myriad Genetics Inc.
17.3.6.1 Company Overview
17.3.6.2 Product Portfolio
17.3.7 Precision Psychiatric Services Inc.
17.3.7.1 Company Overview
17.3.7.2 Product Portfolio
17.3.8 Tempus Labs Inc.
17.3.8.1 Company Overview
17.3.8.2 Product Portfolio
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings